Moreover, high FSCN1 expression was strongly associated with poor clinical outcomes and could be used as a prognostic and predictive biomarker in different cancer types, including nonsmall cell lung cancer 19, urinary bladder urothelial carcinoma 20 and breast cancer 21, 22. Here, FSCN1 is linked to cancer.